[Preliminary clinical study of efficacy on re-treatment for interferon suboptimal CHB patients].
Xue
Rong
R
Nanjing Second Hospital, Nanjing 210003, China. xuerongnj@sina.com
Chang
Jia-bao
JB
Wang
Jian-fang
JF
D000284:Administration, Oral; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009705:Nucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000627:therapeutic use*; D019233:Retreatment; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D009705:Nucleosides; D011744:Pyrimidinones; D000077712:Telbivudine; D007372:Interferons; D000410:Alanine Transaminase; D013936:Thymidine